Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lupus
Biotech
Pfizer makes 'business decision' to end trial of autoimmune drug
Pfizer halted a phase 2 trial of its CXCR5 antibody in an autoimmune blood disorder, while remaining tight-lipped on the program's future.
James Waldron
Oct 20, 2026 6:59am
Amgen reveals 6-point drop in lupus severity behind ph. 2 win
Sep 30, 2026 4:26am
Adicet Bio CAR-T sparks lupus remissions in early-stage trial
Sep 28, 2026 6:45am
Immunovant ends cutaneous lupus program after phase 2 flop
Sep 23, 2026 8:59am
Beeline flies into ph. 3 as oral lupus drug soars past placebo
Sep 9, 2026 7:00am
Alumis crushed by midstage lupus flop but plots path to phase 3
Sep 1, 2026 9:27am